Generic placeholder image

Current Drug Delivery

Editor-in-Chief

ISSN (Print): 1567-2018
ISSN (Online): 1875-5704

Review Article

Monoclonal Antibodies and Antibody-drug Conjugates as Emerging Therapeutics for Breast Cancer Treatment

Author(s): Swati Saini, Nisha Gulati, Rajendra Awasthi, Vimal Arora, Sachin Kumar Singh, Shobhit Kumar, Gaurav Gupta, Kamal Dua, Rakesh Pahwa* and Harish Dureja*

Volume 21, Issue 7, 2024

Published on: 09 August, 2023

Page: [993 - 1009] Pages: 17

DOI: 10.2174/1567201820666230731094258

Price: $65

Abstract

When breast cells divide and multiply out of control, it is called breast cancer. Symptoms include lump formation in the breast, a change in the texture or color of the breast, or a discharge from the nipple. Local or systemic therapy is frequently used to treat breast cancer. Surgical and radiation procedures limited to the affected area are examples of local management. There has been significant worldwide progress in the development of monoclonal antibodies (mAbs) since 1986, when the first therapeutic mAb, Orthoclone OKT3, became commercially available. mAbs can resist the expansion of cancer cells by inducing the destruction of cellular membranes, blocking immune system inhibitors, and preventing the formation of new blood vessels. mAbs can also target growth factor receptors. Understanding the molecular pathways involved in tumor growth and its microenvironment is crucial for developing effective targeted cancer therapeutics. Due to their unique properties, mAbs have a wide range of clinical applications. Antibody-drug conjugates (ADCs) are drugs that improve the therapeutic index by combining an antigen-specific antibody with a payload. This review focuses on the therapeutic applications, mechanistic insights, characteristics, safety aspects, and adverse events of mAbs like trastuzumab, bevacizumab, pertuzumab, ertumaxomab, and atezolizumab in breast cancer treatment. The creation of novel technologies utilizing modified antibodies, such as fragments, conjugates, and multi-specific antibodies, must be a central focus of future studies. This review will help scientists working on developing mAbs to treat cancers more effectively.

Graphical Abstract

[1]
Bayer, V. An overview of monoclonal antibodies. Semin. Oncol. Nurs., 2019, 35(5), 150972.
[http://dx.doi.org/10.1016/j.soncn.2019.08.006]
[2]
Breedveld, F.C. Therapeutic monoclonal antibodies. Lancet, 2000, 355(9205), 735-740.
[http://dx.doi.org/10.1016/S0140-6736(00)01034-5] [PMID: 10703815]
[3]
Nelson, P.N.; Reynolds, G.M.; Waldron, E.E.; Ward, E.; Giannopoulos, K.; Murray, P.G. Monoclonal antibodies. Mol. Pathol., 2000, 53(3), 111-117.
[http://dx.doi.org/10.1136/mp.53.3.111] [PMID: 10897328]
[4]
Zahavi, D.; Weiner, L. Monoclonal antibodies in cancer therapy. Antibodies, 2020, 9(3), 34.
[http://dx.doi.org/10.3390/antib9030034] [PMID: 32698317]
[5]
Shuptrine, C.W.; Surana, R.; Weiner, L.M. Monoclonal antibodies for the treatment of cancer. Semin. Cancer Biol., 2012, 22(1), 3-13.
[http://dx.doi.org/10.1016/j.semcancer.2011.12.009] [PMID: 22245472]
[6]
Mahmuda, A.; Bande, F.; Kadhim Al-Zihiry, K.J.; Abdulhaleem, N.; Majid, R.A.; Hamat, R.A.; Abdullah, W.O.; Unyah, Z. Monoclonal antibodies: A review of therapeutic applications and future prospects. Trop. J. Pharm. Res., 2017, 16(3), 713-722.
[http://dx.doi.org/10.4314/tjpr.v16i3.29]
[7]
Coulson, A.; Levy, A.; Gossell-Williams, M. Monoclonal antibodies in cancer therapy: Mechanisms, successes and limitations. West Indian Med. J., 2014, 63(6), 650-654.
[PMID: 25803383]
[8]
Cui, Y.; Cui, P.; Chen, B.; Li, S.; Guan, H. Monoclonal antibodies: Formulations of marketed products and recent advances in novel delivery system. Drug Dev. Ind. Pharm., 2017, 43(4), 519-530.
[http://dx.doi.org/10.1080/03639045.2017.1278768] [PMID: 28049357]
[9]
Roskos, L.K.; Davis, C.G.; Schwab, G.M. The clinical pharmacology of therapeutic monoclonal antibodies. Drug Dev. Res., 2004, 61(3), 108-120.
[http://dx.doi.org/10.1002/ddr.10346]
[10]
Dang, M.N.; Hoover, E.C.; Scully, M.A.; Sterin, E.H.; Day, E.S. Antibody nanocarriers for cancer management. Curr. Opin. Biomed. Eng., 2021, 19(100295), 1-9.
[PMID: 34423177]
[11]
Pento, J.T. Monoclonal antibodies for the treatment of cancer. Anticancer Res., 2017, 37(11), 5935-5939.
[PMID: 29061772]
[12]
Kimiz-Gebologlu, I.; Gulce-Iz, S.; Biray-Avci, C. Monoclonal antibodies in cancer immunotherapy. Mol. Biol. Rep., 2018, 45(6), 2935-2940.
[http://dx.doi.org/10.1007/s11033-018-4427-x] [PMID: 30311129]
[13]
Hafeez, U.; Gan, H.K.; Scott, A.M. Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. Curr. Opin. Pharmacol., 2018, 41, 114-121.
[http://dx.doi.org/10.1016/j.coph.2018.05.010] [PMID: 29883853]
[14]
Azamjah, N.; Soltan-Zadeh, Y.; Zayeri, F. Global trend of breast cancer mortality rate: A 25-year study. Asian Pac. J. Cancer Prev., 2019, 20(7), 2015-2020.
[http://dx.doi.org/10.31557/APJCP.2019.20.7.2015] [PMID: 31350959]
[15]
Watkins, E.J. Overview of breast cancer. JAAPA, 2019, 32(10), 13-17.
[http://dx.doi.org/10.1097/01.JAA.0000580524.95733.3d] [PMID: 31513033]
[16]
Breast cancer a World Health Organization report.. Available from: https://www.who.int/news-room/fact-sheets/detail/breast-cancer (Accessed on 12 April 2022)
[17]
Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68(6), 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[18]
Sharma, G.N.; Dave, R.; Sanadya, J.; Sharma, P.; Sharma, K.K. Various types and management of breast cancer: An overview. J. Adv. Pharm. Technol. Res., 2010, 1(2), 109-126.
[PMID: 22247839]
[19]
Liu, M.; Yu, X.; Chen, Z.; Yang, T.; Yang, D.; Liu, Q.; Du, K.; Li, B.; Wang, Z.; Li, S.; Deng, Y.; He, N. Aptamer selection and applications for breast cancer diagnostics and therapy. J. Nanobiotechnol., 2017, 15(1), 81.
[http://dx.doi.org/10.1186/s12951-017-0311-4] [PMID: 29132385]
[20]
Akram, M.; Iqbal, M.; Daniyal, M.; Khan, A.U. Awareness and current knowledge of breast cancer. Biol. Res., 2017, 50(1), 33.
[http://dx.doi.org/10.1186/s40659-017-0140-9] [PMID: 28969709]
[21]
Helmi, O.; Elshishiny, F.; Mamdouh, W. Targeted doxorubicin delivery and release within breast cancer environment using PEGylated chitosan nanoparticles labeled with monoclonal antibodies. Int. J. Biol. Macromol., 2021, 184, 325-338.
[http://dx.doi.org/10.1016/j.ijbiomac.2021.06.014] [PMID: 34119547]
[22]
Heim, E.; Valach, L.; Schaffner, L. Coping and psychosocial adaptation: Longitudinal effects over time and stages in breast cancer. Psychosom. Med., 1997, 59(4), 408-418.
[http://dx.doi.org/10.1097/00006842-199707000-00011] [PMID: 9251161]
[23]
Bednarek, A.K.; Sahin, A.; Brenner, A.J.; Johnston, D.A.; Aldaz, C.M. Analysis of telomerase activity levels in breast cancer: Positive detection at the in situ breast carcinoma stage. Clin. Cancer Res., 1997, 3(1), 11-16.
[PMID: 9815531]
[24]
Segal, R.; Evans, W.; Johnson, D.; Smith, J.; Colletta, S.; Gayton, J.; Woodard, S.; Wells, G.; Reid, R. Structured exercise improves physical functioning in women with stages I and II breast cancer: Results of a randomized controlled trial. J. Clin. Oncol., 2001, 19(3), 657-665.
[http://dx.doi.org/10.1200/JCO.2001.19.3.657] [PMID: 11157015]
[25]
Moran, M.S.; Schnitt, S.J.; Giuliano, A.E.; Harris, J.R.; Khan, S.A.; Horton, J.; Klimberg, S.; Chavez-MacGregor, M.; Freedman, G.; Houssami, N.; Morrow, M. Society of surgical oncology-american society for radiation oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Int. J. Radiat. Oncol. Biol. Phys., 2014, 88(3), 553-564.
[26]
Jacquillat, C.; Weil, M.; Baillet, F.; Borel, C.; Auclerc, G.; De Maublanc, M.A.; Housset, M.; Forget, G.; Thill, L.; Soubrane, C.; Khayat, D. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer, 1990, 66(1), 119-129.
[http://dx.doi.org/10.1002/1097-0142(19900701)66:1<119:AID-CNCR2820660122>3.0.CO;2-3] [PMID: 2112976]
[27]
Neuman, H.B.; Morrogh, M.; Gonen, M.; Van Zee, K.J.; Morrow, M.; King, T.A. Stage IV breast cancer in the era of targeted therapy. Cancer, 2010, 116(5), 1226-1233.
[http://dx.doi.org/10.1002/cncr.24873] [PMID: 20101736]
[28]
Nielsen, D.L.; Kümler, I.; Palshof, J.A.E.; Andersson, M. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Breast, 2013, 22(1), 1-12.
[http://dx.doi.org/10.1016/j.breast.2012.09.008] [PMID: 23084121]
[29]
Mohit, E.; Hashemi, A.; Allahyari, M. Breast cancer immunotherapy: Monoclonal antibodies and peptide-based vaccines. Expert Rev. Clin. Immunol., 2014, 10(7), 927-961.
[http://dx.doi.org/10.1586/1744666X.2014.916211] [PMID: 24867051]
[30]
Karly, P. Trastuzumab a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. Adis Drug Evaluation., 2010, 70(2), 215-239.
[31]
Gillian, M. Keating, Pertuzumab in the first-line treatment of HER2-positive metastatic breast cancer. Adis Drug Profile., 2012, 72(3), 353-360.
[32]
Boyiadzis, M.; Foon, K.A. Approved monoclonal antibodies for cancer therapy. Expert Opin. Biol. Ther., 2008, 8(8), 1151-1158.
[http://dx.doi.org/10.1517/14712598.8.8.1151] [PMID: 18613766]
[33]
Kiewe, P.; Thiel, E. Ertumaxomab: A trifunctional antibody for breast cancer treatment. Expert Opin. Investig. Drugs, 2008, 17(10), 1553-1558.
[http://dx.doi.org/10.1517/13543784.17.10.1553] [PMID: 18808314]
[34]
Adams, S.; Diamond, J.R.; Hamilton, E.; Pohlmann, P.R.; Tolaney, S.M.; Chang, C.W.; Zhang, W.; Iizuka, K.; Foster, P.G.; Molinero, L.; Funke, R.; Powderly, J. Atezolizumab Plus nab-Paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-Year survival follow-up a phase 1b clinical trial. JAMA Oncol., 2019, 5(3), 334-342.
[http://dx.doi.org/10.1001/jamaoncol.2018.5152] [PMID: 30347025]
[35]
Nami, B.; Maadi, H.; Wang, Z. Mechanisms underlying the action and synergism of trastuzumab and pertuzumab in targeting HER2-positive breast cancer. Cancers, 2018, 10(10), 342.
[http://dx.doi.org/10.3390/cancers10100342] [PMID: 30241301]
[36]
Greg, L. Trastuzumab a review of its use in the management of HER2-positive metastatic and early-stage breast cancer. Adis Drug Evaluation., 2006, 66(4), 449-475.
[37]
Hudis, C.A. Trastuzumab--mechanism of action and use in clinical practice. N. Engl. J. Med., 2007, 357(1), 39-51.
[http://dx.doi.org/10.1056/NEJMra043186] [PMID: 17611206]
[38]
Levêque, D.; Gigou, L.; Bergerat, J. Clinical pharmacology of trastuzumab. Curr. Clin. Pharmacol., 2008, 3(1), 51-55.
[http://dx.doi.org/10.2174/157488408783329931] [PMID: 18690878]
[39]
Annelies, H.; Boekhout, J.H.; Beijnen, H.M. Trastuzumab. Oncologist, 2011, 16, 800-810.
[40]
McKeage, K.; Perry, C.M. Trastuzumab. Drugs, 2002, 62(1), 209-243.
[http://dx.doi.org/10.2165/00003495-200262010-00008] [PMID: 11790161]
[41]
Bader, A.A.; Schlembach, D.; Tamussino, K.F.; Pristauz, G.; Petru, E. Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy. Lancet Oncol., 2007, 8(1), 79-81.
[http://dx.doi.org/10.1016/S1470-2045(06)71014-2]
[42]
Baselga, J. Clinical trials of Herceptin® (trastuzumab). Eur. J. Cancer, 2001, 37(1), 18-24.
[http://dx.doi.org/10.1016/S0959-8049(00)00404-4] [PMID: 11342196]
[43]
Vogel, C.L.; Melody, A.C.; Debu, T.; John, C.; Gutheil; Lyndsay, N.H.; Louis, F.; Dennis, J.S.; Mureen, M.; Michael, P. Efficacy and safety of trastuzumab as a single agent in first line treatment of HER2 overexpressing metaststic breast cancer. J. Clin. Oncol., 2002, 120(3), 719-726.
[http://dx.doi.org/10.1200/JCO.2002.20.3.719] [PMID: 11821453]
[44]
Jhaveri, K.; Esteva, F.J. Pertuzumab in the treatment of HER2+ breast cancer. J. Natl. Compr. Canc. Netw., 2014, 12(4), 591-598.
[http://dx.doi.org/10.6004/jnccn.2014.0059] [PMID: 24717573]
[45]
Scheuer, W.; Friess, T.; Burtscher, H.; Bossenmaier, B.; Endl, J.; Hasmann, M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res., 2009, 69(24), 9330-9336.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-4597] [PMID: 19934333]
[46]
Bernard-Marty, C.; Lebrun, F.; Awada, A.; Piccart, M.J. Monoclonal antibody-based targeted therapy in breast cancer: Current status and future directions. Drugs, 2006, 66(12), 1577-1591.
[http://dx.doi.org/10.2165/00003495-200666120-00004] [PMID: 16956305]
[47]
Chee, M. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm. Res., 2006, 23(6), 1275-1284.
[48]
Attard, G.; Kitzen, J.; Blagden, S.P.; Fong, P.C.; Pronk, L.C.; Zhi, J.; Zugmaier, G.; Verweij, J.; De Bono, J.S.; De Jonge, M. A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. Br. J. Cancer, 2007, 97(10), 1338-1343.
[PMID: 18000498]
[49]
Barthélémy, P.; Leblanc, J.; Goldbarg, V.; Wendling, F.; Kurtz, J.E. Pertuzumab: Development beyond breast cancer. Anticancer Res., 2014, 34(4), 1483-1491.
[PMID: 24692675]
[50]
Capelan, M.; Pugliano, L.; De Azambuja, E.; Bozovic, I.; Saini, K.S.; Sotiriou, C.; Loi, S.; Piccart-Gebhart, M.J. Pertuzumab: New hope for patients with HER2-positive breast cancer. Ann. Oncol., 2013, 24(2), 273-282.
[http://dx.doi.org/10.1093/annonc/mds328] [PMID: 22910839]
[51]
Baselga, J.; Cortés, J.; Kim, S.B.; Im, S.A.; Hegg, R.; Im, Y.H.; Roman, L.; Pedrini, J.L.; Pienkowski, T.; Knott, A.; Clark, E.; Benyunes, M.C.; Ross, G.; Swain, S.M. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med., 2012, 366(2), 109-119.
[http://dx.doi.org/10.1056/NEJMoa1113216] [PMID: 22149875]
[52]
Gianni, L.; Lladó, A.; Bianchi, G.; Cortes, J.; Kellokumpu-Lehtinen, P.L.; Cameron, D.A.; Miles, D.; Salvagni, S.; Wardley, A.; Goeminne, J.C.; Hersberger, V.; Baselga, J. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol., 2010, 28(7), 1131-1137.
[http://dx.doi.org/10.1200/JCO.2009.24.1661] [PMID: 20124183]
[53]
Nielsen, D.L.; Andersson, M.; Kamby, C. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat. Rev., 2009, 35(2), 121-136.
[http://dx.doi.org/10.1016/j.ctrv.2008.09.003] [PMID: 19008049]
[54]
Presta, L.G.; Chen, H.; O’Connor, S.J.; Chisholm, V.; Meng, Y.G.; Krummen, L.; Winkler, M.; Ferrara, N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res., 1997, 57(20), 4593-4599.
[PMID: 9377574]
[55]
Wang, Y.; Fei, D.; Vanderlaan, M.; Song, A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis, 2004, 7(4), 335-345.
[http://dx.doi.org/10.1007/s10456-004-8272-2] [PMID: 15886877]
[56]
Gordon, M.S.; Margolin, K.; Talpaz, M.; Sledge, G.W., Jr; Holmgren, E.; Benjamin, R.; Stalter, S.; Shak, S.; Adelman, D.C. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol., 2001, 19(3), 843-850.
[http://dx.doi.org/10.1200/JCO.2001.19.3.843] [PMID: 11157038]
[57]
Lyseng-Williamson, K.A.; Robinson, D.M. Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer. BioDrugs, 2006, 20(3), 193-195.
[http://dx.doi.org/10.2165/00063030-200620030-00007] [PMID: 16724868]
[58]
Hamilton, E.P.; Blackwell, K.L. Safety of bevacizumab in patients with metastatic breast cancer. Oncology, 2011, 80(5-6), 314-325.
[http://dx.doi.org/10.1159/000328757] [PMID: 21778772]
[59]
Alexander, T.; Barrière, J.; François, E.; Follana, P. Bevacizumab: A dose review. Crit. Rev. Oncol. Hematol., 2015, 94(3), 311-322.
[http://dx.doi.org/10.1016/j.critrevonc.2015.01.012] [PMID: 25703583]
[60]
Rugo, H.S. Bevacizumab in the treatment of breast Cancer: Rationale and current data. Oncologist, 2004, 9(S1), 43-49.
[http://dx.doi.org/10.1634/theoncologist.9-suppl_1-43] [PMID: 15178815]
[61]
Zeidler, R.; Reisbach, G.; Wollenberg, B. Simultaneous activation of T-cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J. Immunol., 1999, 163(3), 1246-1252.
[PMID: 10415020]
[62]
Riesenberg, R.; Buchner, A.; Pohla, H.; Lindhofer, H. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM × alpha CD3). J. Histochem. Cytochem., 2001, 49(7), 911-917.
[http://dx.doi.org/10.1177/002215540104900711] [PMID: 11410615]
[63]
Riechelmann, H.; Wiesneth, M.; Schauwecker, P. Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: A pilot clinical trial. Cancer Immunol. Immunother., 2007, 56(9), 1397-1406.
[http://dx.doi.org/10.1007/s00262-007-0283-6] [PMID: 17273869]
[64]
Zeidler, R.; Mysliwietz, J.; Csanady, M.; Walz, A.; Ziegler, I.; Schmitt, B.; Wollenberg, B.; Lindhofer, H. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumor cells. Br. J. Cancer, 2000, 83(2), 261-266.
[http://dx.doi.org/10.1054/bjoc.2000.1237] [PMID: 10901380]
[65]
Haense, N.; Atmaca, A.; Pauligk, C.; Steinmetz, K.; Marmé, F.; Haag, G.M.; Rieger, M.; Ottmann, O.G.; Ruf, P.; Lindhofer, H.; Al-Batran, S-E. A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors. BMC Cancer, 2016, 16, 420.
[http://dx.doi.org/10.1186/s12885-016-2449-0] [PMID: 27387446]
[66]
Cardoso, F.; Dirix, L.; Conte, P.F.; Semiglazov, V.; de Placido, S.; Jaeger, M.; Mueller, C.; Eschenbach, B.; Klunker, D.; Lindhofer, H.; Cortes, J. Abstract P3-14-21: Phase II study of single agent trifunctional antibody ertumaxomab (anti-HER-2 and anti-CD3) in HER-2 low expressing hormone-refractory advanced breast cancer patients (ABC). Cancer Res., 2010, 70(24_Supplement), P3-14-21.
[http://dx.doi.org/10.1158/0008-5472.SABCS10-P3-14-21]
[67]
Kiewe, P.; Hasmüller, S.; Kahlert, S.; Heinrigs, M.; Rack, B.; Marmé, A.; Korfel, A.; Jäger, M.; Lindhofer, H.; Sommer, H.; Thiel, E.; Untch, M.; Untch, H. Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin. Cancer Res., 2006, 12(10), 3085-3091.
[http://dx.doi.org/10.1158/1078-0432.CCR-05-2436] [PMID: 16707606]
[68]
Jäger, M.; Schoberth, A.; Ruf, P.; Hess, J.; Lindhofer, H. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Cancer Res., 2009, 69(10), 4270-4276.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-2861] [PMID: 19435924]
[69]
Reddy, S.M.; Carroll, E.; Nanda, R. Atezolizumab for the treatment of breast cancer. Expert Rev. Anticancer Ther., 2020, 20(3), 151-158.
[http://dx.doi.org/10.1080/14737140.2020.1732211] [PMID: 32067545]
[70]
Roy, S.; Soria, J-C.; Kowanetz, M.; Fine, G.D.; Hamid, O.; Gordon, M.S.; Sosman, J.A.; McDermott, D.F.; Powderly, J.D.; Hodi, F.S. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature, 2014, 515(7528), 563-567.
[http://dx.doi.org/10.1038/nature14011] [PMID: 25428504]
[71]
Marchand, M.; Claret, L.; Eppler, S.; Ruppel, J.; Abidoye, O.; Teng, S.L.; Lin, W-T.; Dayog, S.; Bruno, R.; Jin, J.; Girish, S. Clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma. Clin. Pharmacol. Ther., 2017, 102(2), 305-312.
[http://dx.doi.org/10.1002/cpt.587] [PMID: 27981577]
[72]
Heimes, A.S.; Schmidt, M. Atezolizumab for the treatment of triple-negative breast cancer. Expert Opin. Investig. Drugs, 2019, 28(1), 1-5.
[http://dx.doi.org/10.1080/13543784.2019.1552255] [PMID: 30474425]
[73]
Basile, D.; Pelizzari, G.; Vitale, M.G.; Lisanti, C.; Cinausero, M.; Iacono, D.; Puglisi, F. Atezolizumab for the treatment of breast cancer. Expert Opin. Biol. Ther., 2018, 18(5), 595-603.
[http://dx.doi.org/10.1080/14712598.2018.1469619] [PMID: 29690797]
[74]
Henze, A.T.; Mazzone, M. The impact of hypoxia on tumor-associated macrophages. J. Clin. Invest., 2016, 126(10), 3672-3679.
[http://dx.doi.org/10.1172/JCI84427] [PMID: 27482883]
[75]
Thomas, A.; Teicher, B.A.; Hassan, R. Antibody- drug conjugates for cancer therapy. Lancet Oncol., 2016, 17(6), e254-e262.
[http://dx.doi.org/10.1016/S1470-2045(16)30030-4] [PMID: 27299281]
[76]
Chames, P.; Van Regenmortel, M.; Weiss, E.; Baty, D. Therapeutic antibodies: Successes, limitations and hopes for the future. Br. J. Pharmacol., 2009, 157(2), 220-233.
[http://dx.doi.org/10.1111/j.1476-5381.2009.00190.x] [PMID: 19459844]
[77]
Jackson, D.; Atkinson, J.; Guevara, C.I.; Zhang, C.; Kery, V.; Moon, S.; Virata, C.; Yang, P.; Lowe, C.; Pinkstaff, J.; Cho, H.; Knudsen, N.; Manibusan, A.; Tian, F.; Sun, Y.; Lu, Y.; Sellers, A.; Jia, X-C.; Joseph, I.; Anand, B.; Morrison, K.; Pereira, D.S.; Stover, D. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates. PLoS One, 2014, 9(1), e83865.
[http://dx.doi.org/10.1371/journal.pone.0083865] [PMID: 24454709]
[78]
Christopher, R.; Edward, H.H.; Lawrence, L.C.; Simeon, B.; Probst, G.; Fitch-Bruhns, M.; Monteon, J.; Bermudez, A.; van der Horst, E.H.; Halcomb, R.L.; Jackson, D.Y. Antibody-Drug Conjugates (ADCs) derived from interchain cysteine cross-linking demonstrate improved homogeneity and other pharmacological properties over conventional heterogeneous ADCs. Mol. Pharm., 2015, 12(11), 3986-3998.
[http://dx.doi.org/10.1021/acs.molpharmaceut.5b00432] [PMID: 26393951]
[79]
Svetlana, O.; Toki, B.E.; Torgov, M.Y.; Mendelsohn, B.A.; Wahl, A.F.; Meyer, D.L.; Senter, P.D. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol., 2003, 21(7), 778-784.
[http://dx.doi.org/10.1038/nbt832] [PMID: 12778055]
[80]
Wagner-Rousset, E.; Janin-Bussat, M-C.; Beck, A. Antibody-drug conjugate model fast characterization by LC-MS following IdeS proteolytic digestion. MAbs, 2014, 6(1), 273-285.
[http://dx.doi.org/10.4161/mabs.26773] [PMID: 24135617]
[81]
Alicia, F.C. Investigational antibody- drug conjugates in clinical trials for the treatment of breast cancer. Expert Opin. Investig Drugs, 2021, 30(8), 789-795.
[http://dx.doi.org/10.1080/13543784.2021.1940950] [PMID: 34114911]
[82]
Ferraro, E.; Drago, J.Z.; Modi, S. Implementing antibody-drug conjugates(ADCs) in HER2-positive breast cancer: State of the art and future directions. Breast Cancer Res., 2021, 23(1), 84.
[http://dx.doi.org/10.1186/s13058-021-01459-y] [PMID: 34380530]
[83]
Jessica, R.; Owen, S.C. Antibody drug conjugates: Design and selection of linker, payload and conjugation chemistry. AAPS J., 2015, 17(2), 339-351.
[http://dx.doi.org/10.1208/s12248-014-9710-8] [PMID: 25604608]
[84]
Heidi, L.; Cardarelli, P.M.; Deshpande, S.; Borzilleri, R.M. Antibody-drug conjugates: Current status and future directions. Drug Discov. Today, 2014, 19(7), 869-881.
[http://dx.doi.org/10.1016/j.drudis.2013.11.004] [PMID: 24239727]
[85]
Jefferis, R. Antibody therapeutics. Expert Opin. Biol. Ther., 2007, 7(9), 1401-1413.
[http://dx.doi.org/10.1517/14712598.7.9.1401] [PMID: 17727329]
[86]
Jochen, G. Isotype selection in antibody engineering. Nat. Biotechnol., 2007, 25(12), 1369-1372.
[http://dx.doi.org/10.1038/nbt1207-1369] [PMID: 18066027]
[87]
Eiger, D.; Agostinetto, E.; Saude-Conde, R.; De Azambuja, E. The exciting new field of her2-low breast cancer treatment. Cancers, 2021, 13(5), 1015.
[http://dx.doi.org/10.3390/cancers13051015] [PMID: 33804398]
[88]
Jain, N.; Smith, S.W.; Ghone, S.; Tomczuk, B. Current ADC linker chemistry. Pharm. Res., 2015, 32(11), 3526-3540.
[http://dx.doi.org/10.1007/s11095-015-1657-7] [PMID: 25759187]
[89]
Joshua, Z. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat. Rev. Clin. Oncol., 2021, 18(6), 327-344.
[http://dx.doi.org/10.1038/s41571-021-00470-8] [PMID: 33558752]
[90]
Tsuchikama, K.; An, Z. Antibody-drug conjugates: Recent advances in conjugation and linker chemistries. Protein Cell, 2018, 9(1), 33-46.
[http://dx.doi.org/10.1007/s13238-016-0323-0] [PMID: 27743348]
[91]
Criscitiello, C.; Morganti, S.; Curigliano, G. Antibody-drug conjugates in solid tumors: A look into novel targets. J. Hematol. Oncol., 2021, 14(1), 20.
[http://dx.doi.org/10.1186/s13045-021-01035-z] [PMID: 33509252]
[92]
Wayne, C. Factors involved in the design of cytotoxic payloads for antibody-drug conjugates. In: Antibody-Drug Conjugates and Immunotoxins; Springer: New York, NY, 2013.
[93]
Juan, A.; Cimas, F.J.; Bravo, I.; Pandiella, A.; Ocaña, A.; Alonso-Moreno, C. Antibody conjugation of nanoparticle as therapeutics for breast cancer treatment. Int. J. Mol. Sci., 2020, 21(17), 6018.
[http://dx.doi.org/10.3390/ijms21176018]
[94]
Trail, P.A.; Dubowchik, G.M.; Lowinger, T.B. Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design. Pharmacol. Ther., 2018, 181, 126-142.
[http://dx.doi.org/10.1016/j.pharmthera.2017.07.013] [PMID: 28757155]
[95]
Aram, J.; Ibrahim, M.F.; Saifo, M.S. Antibody-drug conjugates used in breast cancers. J. Oncol., 2021, 2021, 9927433.
[http://dx.doi.org/10.1155/2021/9927433] [PMID: 34257655]
[96]
Rinnerthaler, G.; Gampenrieder, S.; Greil, R. HER2 directed antibody-drug-conjugates beyond T-DM1 in breast cancer. Int. J. Mol. Sci., 2019, 20(5), 1115.
[http://dx.doi.org/10.3390/ijms20051115] [PMID: 30841523]
[97]
Le Joncour, V.; Martins, A.; Puhka, M.; Isola, J.; Salmikangas, M.; Laakkonen, P.; Joensuu, H.; Barok, M. A novel anti- HER2 antibody-drug conjugate XMT-1522 for HER2-positive breast and gastric cancers resistant to trastuzumab emtansine. Mol. Cancer Ther., 2019, 18(10), 1721-1730.
[http://dx.doi.org/10.1158/1535-7163.MCT-19-0207] [PMID: 31292166]
[98]
Pondé, N.; Aftimos, P.; Piccart, M. Antibody-drug conjugates in breast cancer: A comprehensive review, current treatments. Curr. Treat. Options Oncol., 2019, 20(5), 37.
[http://dx.doi.org/10.1007/s11864-019-0633-6] [PMID: 30931493]
[99]
U.S. National Institutes of Health. anti-HER2 antibody-drug conjugate MEDI4276. 2020. Available from: https://www.cancer .gov/ publications/dictionaries/cancer-drug/def/anti-her2-vc0101-adc-pf-06804103
[100]
Altunay, B.; Morgenroth, A.; Beheshti, M.; Vogg, A.; Wong, N.C.L.; Ting, H.H.; Biersack, H-J.; Stickeler, E.; Mottaghy, F.M. HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging. Eur. J. Nucl. Med. Mol. Imaging, 2021, 48(5), 1371-1389.
[101]
Tymon-Rosario, J.; Bonazzoli, E.; Bellone, S.; Manzano, A.; Pelligra, S.; Guglielmi, A.; Gnutti, B.; Nagarkatti, N.; Zeybek, B.; Manara, P.; Zammataro, L.; Harold, J.; Mauricio, D.; Buza, N.; Hui, P.; Altwerger, G.; Menderes, G.; Ratner, E.; Clark, M.; Andikyan, V.; Huang, G.S.; Silasi, D-A.; Azodi, M.; Schwartz, P.E.; Santin, A.D. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. Gynecol. Oncol., 2021, 163(2), 334-341.
[102]
Lee, B.; Park, M-H.; Byeon, J-J.; Shin, S-H.; Choi, J.; Park, Y.; Park, Y-H.; Chae, J.; Shin, Y.G. Quantification of an antibody-conjugated drug in fat plasma by an affinity capture LC-MS/MS method for a novel prenyl transferase-mediated site-specific antibody–drug conjugate. Molecules, 2020, 25(7), 1515.
[http://dx.doi.org/10.3390/molecules25071515]
[103]
Deeks, E. Disitamab vedotin: First approval. Drugs, 2021, 81(16), 1929-1935.
[104]
Review, A.D.C. Hertuzumab vedotin;. 2020. Available from: https://www.adcreview.com/drugmap/hertuzumab-vedotin/
[105]
Li, Hongwen; Yu, Chao; Jiang, Jing; Huang, Changjiang; Yao, Xuejing; Xu, Qiaoyu; Yu, Fang; Lou, Liguang; Fang, Jianmin An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer. Cancer Biol. Ther., 2016, 17(4), 346-354.
[106]
Faria, M.; Peay, M.; Lam, B.; Ma, E.; Yuan, M.; Waldron, M.; Mylott, W.R., Jr; Liang, M.; Rosenbaum, A.I. Multiplex LC-MS/MS Assays for Clinical Bioanalysis of MEDI4276, an antibody-drug conjugate of tubulysin analogue attached via cleavable linker to a biparatopic humanized antibody against HER-2. Antibodies, 2019, 8(1), 11.
[107]
Avilés, P.; Domínguez, J.M.; Guillén, M.J.; Muñoz-Alonso, M.J.; Mateo, C.; Rodriguez-Acebes, R.; Molina-Guijarro, J.M.; Francesch, A.; Martínez-Leal, J.F.; Munt, S.; Galmarini, C.M.; Cuevas, C. MI130004, a novel antibody-drug conjugate combining trastuzumab with a molecule of marine origin, shows outstanding in vivo activity against HER2-expressing tumors. Mol. Cancer Ther., 2018, 17(4), 786-794.
[http://dx.doi.org/10.1158/1535-7163.MCT-17-0795] [PMID: 29440297]
[108]
Conjugates, A.R.J.A-D. MI130004. 2020. Available from: https://www.adcreview.com/drugmap/mi130004/
[109]
Xu, Z.; Guo, D.; Jiang, Z.; Tong, Rongsheng; Jiang, Peidu; Bai, Lan; Chen, Lu; Zhu, Yuxuan; Guo, Chun; Shi, Jianyou; Yu, Dongke Novel HER2-targeting antibody- drug conjugates of trastuzumab beyond T-DM1 in breast cancer: Trastuzumab deruxtecan (DS-8201a) and (Vic-) trastuzumab duocarmazine (SYD985). Eur. J. Med. Chem., 2019, 183, 111682.
[110]
Conjugates, A.R.J.A-D. Trastuzumab duocarmazine |SYD985 | Trastuzumab vc- seco-DUBA. 2020. Available from: https://www.adcreview.com/drugmap/trastuzumabduocarmazinesyd985/
[111]
Yin, L.; Duan, J.J.; Bian, X.W.; Yu, S. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res., 2020, 22(1), 61.
[http://dx.doi.org/10.1186/s13058-020-01296-5] [PMID: 32517735]
[112]
Monoclonal antibody therapy in treating women with locally advanced or metastatic breast cancer previously treated with combination chemotherapy. NCT00066547, , 2003.
[113]
Clinical study of recombinant anti-her2 humanized monoclonal antibody for injection. NCT04170595,, 2019.
[114]
Atezolizumab, cobimetinib, and eribulin in treating patients with chemotherapy resistant metastatic inflammatory breast cancer. NCT03202316, , 2017.
[115]
Testing the drug atezolizumab or placebo with usual therapy in first-line HER2-positive metastatic breast cancer. NCT03199885, , 2017.
[116]
Inetetamab plus cyclophosphamide metronomic chemotherapy plus aromatase inhibitor in metastatic HER2+/HR+ breast cancer (Increase). NCT04941885, , 2021.
[117]
Carboplatin and paclitaxel with or without panitumumab in treating patients with invasive triple negative breast cancer. NCT02876107, , 2016.
[118]
Olaparib in combination with either durvalumab, selumetinib, or capivasertib or ceralasertib alone in treating patients with metastatic triple negative breast cancer. NCT03801369, , 2023.
[119]
Dong, W.; Shi, J.; Yuan, T.; Qi, B.; Yu, J.; Dai, J.; He, L. Antibody-drug conjugates of 7-ethyl-10-hydroxycamptothecin: Sacituzumab govitecan and labetuzumab govitecan. Eur. J. Med. Chem., 2019, 167, 583-593.
[http://dx.doi.org/10.1016/j.ejmech.2019.02.017] [PMID: 30822636]
[120]
Bardia, A.; Mayer, I.A.; Vahdat, L.T.; Tolaney, S.M.; Isakoff, S.J.; Diamond, J.R.; O’Shaughnessy, J.; Moroose, R.L.; Santin, A.D.; Abramson, V.G.; Shah, N.C.; Rugo, H.S.; Goldenberg, D.M.; Sweidan, A.M.; Iannone, R.; Washkowitz, S.; Sharkey, R.M.; Wegener, W.A.; Kalinsky, K. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N. Engl. J. Med., 2019, 380(8), 741-751.
[http://dx.doi.org/10.1056/NEJMoa1814213] [PMID: 30786188]
[121]
Nagayama, A.; Vidula, N; Ellisen, L; Bardia, A Novel antibody-drug conjugates for triple negative breast cancer. Ther. Adv. Med. Oncol., 2020, 12, 1758835920915980.
[http://dx.doi.org/10.1177/1758835920915980] [PMID: 32426047]
[122]
Sussman, D.; Smith, L.M.; Anderson, M.E.; Duniho, S.; Hunter, J.H.; Kostner, H.; Miyamoto, J.B.; Nesterova, A.; Westendorf, L.; Van Epps, H.A.; Whiting, N.; Benjamin, D.R. SGN-LIV1A: A novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer. Mol. Cancer Ther., 2014, 13(12), 2991-3000.
[http://dx.doi.org/10.1158/1535-7163.MCT-13-0896] [PMID: 25253783]
[123]
Hashimoto, Y.; Koyama, K.; Kamai, Y.; Hirotani, K.; Ogitani, Y.; Zembutsu, A.; Abe, M.; Kaneda, Y.; Maeda, N.; Shiose, Y.; Iguchi, T.; Ishizaka, T.; Karibe, T.; Hayakawa, I.; Morita, K.; Nakada, T.; Nomura, T.; Wakita, K.; Kagari, T.; Abe, Y.; Murakami, M.; Ueno, S.; Agatsuma, T. A novel HER3- targeting antibody-drug conjugate, U3-1402, exhibits potent therapeutic efficacy through the delivery of cytotoxic payload by efficient internalization. Clin. Cancer Res., 2019, 25(23), 7151-7161.
[http://dx.doi.org/10.1158/1078-0432.CCR-19-1745] [PMID: 31471314]
[124]
Bayerlová, M.; Menck, K.; Klemm, F.; Wolff, A.; Pukrop, T.; Binder, C.; Beißbarth, T.; Bleckmann, A. Ror2 signaling and its relevance in breast cancer progression. Front. Oncol., 2017, 7, 135.
[http://dx.doi.org/10.3389/fonc.2017.00135] [PMID: 28695110]
[125]
Trombe, M.; Caron, A.; Tellier, A.; Carrez, C.; Guérif, S.; Clavier, S.; Karst, N.; Saarinen, J.; Satomaa, T.; Pitkänen, V.; Aitio, O.; Heiskanen, A.; Fassan, M.; Pinkas, J.; Baffa, R.; Blanc, V.; Nicolazzi, C. Abstract 235: Preclinical activity of an antibody drug conjugate targeting tumor specificmuc1 structural peptide-glycotope. Cancer Res., 2019, 79(13_Supplement), 235.
[http://dx.doi.org/10.1158/1538-7445.AM2019-235]
[126]
Fu, Z.; Li, S.; Han, S.; Shi, C.; Zhang, Y. Antibody drug conjugate: The “biological missile” for targeted cancer therapy. Signal Transduct. Target. Ther., 2022, 7(1), 93.
[http://dx.doi.org/10.1038/s41392-022-00947-7] [PMID: 35318309]
[127]
Mercogliano, M.F.; Bruni, S.; Mauro, F.L.; Schillaci, R. Emerging targeted therapies for HER2-positive breast cancer. Cancers, 2023, 15(7), 1987.
[http://dx.doi.org/10.3390/cancers15071987] [PMID: 37046648]
[128]
Swain, S.M.; Miles, D.; Kim, S.B.; Im, Y.H.; Im, S.A.; Semiglazov, V.; Ciruelos, E.; Schneeweiss, A.; Loi, S.; Monturus, E.; Clark, E.; Knott, A.; Restuccia, E.; Benyunes, M.C.; Cortés, J.; Agajanian, R.; Ahmad, R.; Aktas, B.; Alencar, V.H.; Amadori, D.; Andrade, J.; André Franke, F.; Angiolini, C.; Aogi, K.; Armor, J.; Arpornwirat, W.; Assersohn, L.; Audeh, W.; Aulitzky, W.; Azevedo, S.; Bartoli, M.A.; Batista Lopez, N.; Bianconi, M.; Biganzoli, L.; Birhiray, R.; Bitina, M.; Blachy, R.; Blackwell, K.; Blanchard, R.; Blanchet, P.; Boiangiu, I.; Bower, B.; Brezden-Masley, C.; Brufsky, A.; Budde, L.; Caguioa, P.; Calvo, L.; Campone, M.; Carroll, R.R.; Castro, H.; Chan, V.; Charu, V.; Cinieri, S.; Clemens, M.; Conejo, E.A.; Côrtes, E.; Coudert, B.; Cronemberger, E.; Cubero, D.; Dakhil, S.; Daniel, B.; Davidson, N.; De Fatima Gaui, M.; De La Cruz, S.; Del Pilar, M.; Delgado, G.; Ellerton, J.A.; Estuardo, C.; Fehrenbacher, L.; Ferrero, J-M.; Flynn, P.J.; Foszczynska-Kloda, M.; Franco, S.; Fujii, H.; Gallagher, C.; Gamucci, T.; Giacomi, N.; Gil I Gil, M.; Gonzalez Martin, A.; Gorbunova, V.; Gotovkin, E.; Green, N.; Grincuka, E.; Grischke, E-M.; Hansen, V.; Hargis, J.; Hauschild, M.; Hegg, R.; Hendricks, C.; Hermann, R.; Hoff, P.; Horiguchi, J.; Hornedo Muguiro, J.; Iacobelli, S.; Inoue, K.; Ismael, G.; Itoh, Y.; Iwata, D.H.; Jendiroba, D.; Jochim, R.; Jones, A.; Just, M.; Kallab, A.; Karwal, M.; Kashiwaba, M.; Kato, G.; Kaufman, P.A.; Kellokumpu-Lehtinen, P.; Kirsch, A.; Kiselev, I.; Klein, P.; Kohno, N.; Kopp, M.; Kostovska-Maneva, L.; Kotliar, M.; Kudaba, I.; Kümmel, S.; Kuroi, K.; Lacava, J.; Latini, L.; Lee, S.C.; Lichinitser, M.; Lobo, C.; Maintz, C.; Maneecahvakajorn, J.; Marmé, A.; Martinez, G.; Masuda, N.; Matwiejuk, M.; Merculov, V.; Michaelson, R.; Miguel, L.; Monroy, H.; Montemurro, F.; Morales, S.; Moura, R.; Mueller, V.; Mulatero, C.; Nakagami, K.; Nakayama, T.; Neidhart, J.; Nguyen, A.; Nishimura, R.; Ogata, H.; O’reilly, S.; O’rourke, T.; Otero Reye, D.; Ouyang, X.; Patel, R.; Patel, T.; Pedrini, J.L.; Pereira, R.; Perez, A.; Peterson, C.; Pienkowski, T.; Pinczowski, H.; Polikoff, J.; Polkowski, W.; Price, P.E.; Prill, S.; Priou, F.; Purkalne, G.; Pyrhoenen, S.; Quackenbush, R.; Rai, Y.; Ribelles, N.; Ro, J.; Robinson, A.; Robles, R.; Rodriguez, G.; Roman, L.; Saji, S.; Sanchez-Rovira, P.; Sato, N.; Schmidt, M.; Schumacher, C.; Senecal, F.; Sharma, P.; Shen, Z.; Shirinkin, V.; Simoncini, E.; Sirisinha, T.; Smith, R.; Sohn, J-H.; Soldic, Z.; Soria, T.; Spicer, D.; Srimuninnimit, V.; Sriuranpong, V.; Staroslawska, E.; Stefanovski, P.; Sunpaweravong, P.; Taguchi, J.; Takeda, K.; Tellez-Trevilla, G.; Thomas, R.; Thomssen, C.; Toache, Z.; Tokuda, Y.; Tomczak, P.; Tosello, C.; Tsugawa, K.; Tudtud, D.; Ueno, T.; Van Eyll, B.; Varela, M.; Vasev, N.; Vrbanec, D.; Wang, X.; Wang, L.; Watanabe, J.; Waterhouse, D.; Wesenberg, B.; Wheatley, D.; Wong, Z.W.; Yadav, S.; Yadav, S.; Yardley, D.; Yau, T-K.; Yeo, W.; Ying, C.; Youn Oh, D. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol., 2020, 21(4), 519-530.
[http://dx.doi.org/10.1016/S1470-2045(19)30863-0] [PMID: 32171426]
[129]
Abuhelwa, Z.; Alloghbi, A.; Nagasaka, M. A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC). Cancer Treat. Rev., 2022, 106, 102393.
[http://dx.doi.org/10.1016/j.ctrv.2022.102393] [PMID: 35472631]
[130]
Jeon, E.J.; Han, J.H.; Seo, Y.; Koh, E.M.; Han, K.H.; Hwang, K.; Jung, K.J. Implementation of systematic bioanalysis of antibody–drug conjugates for preclinical pharmacokinetic study of ado-trastuzumab emtansine (T-DM1) in rats. Pharmaceutics, 2023, 15(3), 756.
[http://dx.doi.org/10.3390/pharmaceutics15030756] [PMID: 36986616]
[131]
Liu, T.; Tao, Y.; Xia, X.; Zhang, Y.; Deng, R.; Wang, Y. Analytical tools for antibody-drug conjugates: From in vitro to in vivo. Trends Analyt. Chem., 2022, 152, 116621.
[http://dx.doi.org/10.1016/j.trac.2022.116621]
[132]
Fumagalli, C.; Ranghiero, A.; Gandini, S.; Corso, F.; Taormina, S.; De Camilli, E.; Rappa, A.; Vacirca, D.; viale, G.; Guerini-Rocco, E.; Barberis, M. Inter-tumor genomic heterogeneity of breast cancers: Comprehensive genomic profile of primary early breast cancers and relapses. Breast Cancer Res., 2020, 22(1), 107.
[http://dx.doi.org/10.1186/s13058-020-01345-z] [PMID: 33059724]
[133]
Najjar, S.; Allison, K.H. Updates on breast biomarkers. Virchows Arch., 2022, 480(1), 163-176.
[http://dx.doi.org/10.1007/s00428-022-03267-x] [PMID: 35029776]
[134]
Cruz, E.; Kayser, V. Monoclonal antibody therapy of solid tumors: Clinical limitations and novel strategies to enhance treatment efficacy. Biologics, 2019, 13, 33-51.
[http://dx.doi.org/10.2147/BTT.S166310] [PMID: 31118560]
[135]
Redig, A.J.; McAllister, S.S. Breast cancer as a systemic disease: A view of metastasis. J. Intern. Med., 2013, 274(2), 113-126.
[http://dx.doi.org/10.1111/joim.12084] [PMID: 23844915]

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy
Request history8.2.27PHP Version271msRequest Duration28MBMemory UsageGET article/{article_id}/{param?}Route
  • warninglog[20:11:35] LOG.warning: Optional parameter $article_id declared before required parameter $request i...
  • warninglog[20:11:35] LOG.warning: Function strftime() is deprecated in /home/alphaeurekaselec/public_html/stor...
  • warninglog[20:11:35] LOG.warning: trim(): Passing null to parameter #1 ($string) of type string is deprecated ...
  • warninglog[20:11:35] LOG.warning: Function strftime() is deprecated in /home/alphaeurekaselec/public_html/stor...
  • Booting (103ms)time
  • Application (168ms)time
  • 1 x Application (61.92%)
    168ms
    1 x Booting (38.08%)
    103ms
    14 templates were rendered
    • articlearticle.blade.php#?blade
    • includes.article_top_bannerarticle_top_banner.blade.php#?blade
    • includes.article_referencearticle_reference.blade.php#?blade
    • export_citation_formexport_citation_form.blade.php#?blade
    • includes.article_bottom_bannerarticle_bottom_banner.blade.php#?blade
    • includes.inc_related_journalsinc_related_journals.blade.php#?blade
    • includes.inc_related_ebooksinc_related_ebooks.blade.php#?blade
    • includes.journal_rightmenujournal_rightmenu.blade.php#?blade
    • includes.journal_right_bannerjournal_right_banner.blade.php#?blade
    • layouts.appapp.blade.php#?blade
    • layouts._login_access_login_access.blade.php#?blade
    • layouts._header_header.blade.php#?blade
    • layouts._main_menu_main_menu.blade.php#?blade
    • layouts._footer_menu_footer_menu.blade.php#?blade
    uri
    GET article/{article_id}/{param?}
    middleware
    web, check_user_access
    controller
    App\Http\Controllers\ArticleController@GetArticleDetails
    namespace
    App\Http\Controllers
    where
    as
    article
    file
    app/Http/Controllers/ArticleController.php:1974-2510
    36 statements were executed, 4 of which were duplicates, 32 unique. Show only duplicated94.73ms
    • Connection Establishedalphaeurekaselec_live_10_06_2022UserAccessCheck.php#24
      Backtrace
      • 9. middleware::check_user_access:24
      • 10. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 11. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 12. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 13. vendor/laravel/framework/src/Illuminate/Foundation/Http/Middleware/VerifyCsrfToken.php:88
    • INSERT INTO visitor_ip_address (ip_address,visitor_agent,visitor_count, created_on,updated_on) VALUES ('51271243','',1,1740514295,1740514295) ON DUPLICATE KEY UPDATE visitor_count=visitor_count + 1, updated_on=1740514295
      920μsalphaeurekaselec_live_10_06_2022UserAccessCheck.php#24
      Backtrace
      • 11. middleware::check_user_access:24
      • 12. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 14. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 15. vendor/laravel/framework/src/Illuminate/Foundation/Http/Middleware/VerifyCsrfToken.php:88
    • INSERT INTO visitor_ip_address_detail (ip_address,visitor_url,visitor_count, created_on,updated_on) VALUES ('51271243','/article/133248',1,1740514295,1740514295)
      150μsalphaeurekaselec_live_10_06_2022UserAccessCheck.php#27
      Backtrace
      • 11. middleware::check_user_access:27
      • 12. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 14. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 15. vendor/laravel/framework/src/Illuminate/Foundation/Http/Middleware/VerifyCsrfToken.php:88
    • (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_journal_volume_trail WHERE to_ip >= 51271243 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51271243) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_journal_volume_corporate WHERE to_ip >= 51271243 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51271243) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_journal_volume_token WHERE to_ip >= 51271243 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51271243) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_ebook_volume_trail WHERE to_ip >= 51271243 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51271243) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_ebook_volume_corporate WHERE to_ip >= 51271243 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51271243) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_ebook_volume_token WHERE to_ip >= 51271243 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51271243) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_issue_trail WHERE to_ip >= 51271243 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51271243) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_issue_corporate WHERE to_ip >= 51271243 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51271243) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_issue_token WHERE to_ip >= 51271243 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51271243) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_article_trail WHERE to_ip >= 51271243 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51271243) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_article_corporate WHERE to_ip >= 51271243 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51271243) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_article_token WHERE to_ip >= 51271243 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51271243) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_chapter_trail WHERE to_ip >= 51271243 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51271243) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_chapter_corporate WHERE to_ip >= 51271243 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51271243) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_chapter_token WHERE to_ip >= 51271243 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51271243) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_disease_corporate WHERE to_ip >= 51271243 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 51271243) limit 1
      17.23msalphaeurekaselec_live_10_06_2022UserAccess.php#784
      Bindings
      • 0: 51271243
      • 1: 51271243
      • 2: 51271243
      • 3: 51271243
      • 4: 51271243
      • 5: 51271243
      • 6: 51271243
      • 7: 51271243
      • 8: 51271243
      • 9: 51271243
      • 10: 51271243
      • 11: 51271243
      • 12: 51271243
      • 13: 51271243
      • 14: 51271243
      • 15: 51271243
      Backtrace
      • 14. app/Models/UserAccess/UserAccess.php:784
      • 15. middleware::check_user_access:114
      • 16. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 18. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
    • SELECT at.type_name, p.copyright, p.publisher_location,m.month,y.year, a.publish_on, a.nid article_nid,a.article_id, a.pmid, a.issue_id, a.title, a.abstract,a.podcast,a.altmetric_score,a.altmetric_url,a.kudos_url, a.page_count, a.first_page, a.elocator, a.last_page, i.publication_date, a.file_name, a.file_path, a.doi, a.is_epub,a.epub_type, a.volume_id, a.is_uploaded, a.editor_choice, a.is_epub, j.image_file_name, a.article_no, a.art_type AS article_type, a.supplementary_filename,a.html_filename,a.prc_filename,a.epub_filename, a.graph_abs_lg_filename, a.graph_abs_sm_filename, a.oa_image_lg_filename, a.oa_image_sm_filename, j.journal_banner,a.animated_abstract,a.erratum_in,a.erratum_for, (CASE WHEN a.issue_id =0 THEN j.epub_price ELSE j.price END) AS sell_price, j.epub_price, j.nid AS jour_nid, j.title AS journal_title, j.issn, j.eissn,j.journal_id, j.subtitle AS jour_subtitle, v.volume_id,v.volume_name AS volume, v.year_id, i.title AS issue, i.month_id ,i.type issue_type, j.subtitle,j.formerly_title, ac.subtitle AS epub_title,a.crossmark_enabled,a.text_mining_urls,a.license_urls,a.created, a.receivedate, a.revisedate, a.acceptdate,js.js_title FROM article a LEFT JOIN article_section ac ON a.is_epub = ac.art_sec_id LEFT JOIN journal_section js ON a.js_id = js.js_id LEFT JOIN article_type at ON a.art_type = at.art_type_id LEFT JOIN issue i ON a.issue_id = i.issue_id LEFT JOIN month m ON m.id = i.month_id LEFT JOIN volume v ON v.volume_id = a.volume_id INNER JOIN year y ON y.id = v.year_id INNER JOIN journal j ON j.journal_id = a.journal_id INNER JOIN publisher p ON p.publisher_id = j.publisher_id WHERE a.article_id=133248
      1.04msalphaeurekaselec_live_10_06_2022Article.php#408
      Backtrace
      • 11. app/Models/Article.php:408
      • 12. app/Http/Controllers/ArticleController.php:2515
      • 13. app/Http/Controllers/ArticleController.php:2035
      • 14. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 15. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select * from `journal` where `journal_id` = 18 limit 1
      1.09msalphaeurekaselec_live_10_06_2022Journal.php#64
      Bindings
      • 0: 18
      Backtrace
      • 14. app/Models/Journal.php:64
      • 15. app/Http/Controllers/ArticleController.php:2516
      • 16. app/Http/Controllers/ArticleController.php:2035
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select count(*) as aggregate from (select j.nid as journal_nid,j.flyer_link,j.title ,j.issn,j.eissn,j.keyword, j.journal_id as journal_id, j.subtitle, j.image_file_name,j.description,j.journal_insight_url,j.doi from `subject_journal` as `sj` inner join `journal` as `j` on `j`.`journal_id` = `sj`.`journal_id` where j.journal_status=1 and subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=18) and sj.journal_id!=18 group by `j`.`nid`) as `aggregate_table`
      1.47msalphaeurekaselec_live_10_06_2022Subject.php#200
      Backtrace
      • 16. app/Models/Subject.php:200
      • 17. app/Http/Controllers/ArticleController.php:2517
      • 18. app/Http/Controllers/ArticleController.php:2035
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 20. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select j.nid as journal_nid,j.flyer_link,j.title ,j.issn,j.eissn,j.keyword, j.journal_id as journal_id, j.subtitle, j.image_file_name,j.description,j.journal_insight_url,j.doi from `subject_journal` as `sj` inner join `journal` as `j` on `j`.`journal_id` = `sj`.`journal_id` where j.journal_status=1 and subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=18) and sj.journal_id!=18 group by `j`.`nid` order by `j`.`journal_id` asc limit 10 offset 0
      1.28msalphaeurekaselec_live_10_06_2022Subject.php#200
      Backtrace
      • 14. app/Models/Subject.php:200
      • 15. app/Http/Controllers/ArticleController.php:2517
      • 16. app/Http/Controllers/ArticleController.php:2035
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select count(*) as aggregate from (select v.nid as volume_id,e.nid,e.title,v.issn,v.eissn,v.isbn,v.eisbn,e.ebook_id, v.image_file_name,v.file_path,v.flyer_link,v.ebook_volume_id, v.volume_name,v.doi,v.year_id,v.introduction from `subject_ebook` as `se` inner join `ebook` as `e` on `e`.`ebook_id` = `se`.`ebook_id` inner join `ebook_volume` as `v` on `v`.`ebook_id` = `se`.`ebook_id` inner join `year` as `y` on `y`.`id` = `v`.`year_id` where subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=18) and v.ebook_status='1' and y.year > 2020 group by `v`.`nid`) as `aggregate_table`
      2.62msalphaeurekaselec_live_10_06_2022Subject.php#220
      Backtrace
      • 16. app/Models/Subject.php:220
      • 17. app/Http/Controllers/ArticleController.php:2518
      • 18. app/Http/Controllers/ArticleController.php:2035
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 20. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select v.nid as volume_id,e.nid,e.title,v.issn,v.eissn,v.isbn,v.eisbn,e.ebook_id, v.image_file_name,v.file_path,v.flyer_link,v.ebook_volume_id, v.volume_name,v.doi,v.year_id,v.introduction from `subject_ebook` as `se` inner join `ebook` as `e` on `e`.`ebook_id` = `se`.`ebook_id` inner join `ebook_volume` as `v` on `v`.`ebook_id` = `se`.`ebook_id` inner join `year` as `y` on `y`.`id` = `v`.`year_id` where subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=18) and v.ebook_status='1' and y.year > 2020 group by `v`.`nid` order by `v`.`ebook_volume_id` desc limit 10 offset 0
      1.51msalphaeurekaselec_live_10_06_2022Subject.php#220
      Backtrace
      • 14. app/Models/Subject.php:220
      • 15. app/Http/Controllers/ArticleController.php:2518
      • 16. app/Http/Controllers/ArticleController.php:2035
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select * from `keywords` where `article_id` = '133248'
      190μsalphaeurekaselec_live_10_06_2022Keywords.php#43
      Bindings
      • 0: 133248
      Backtrace
      • 13. app/Models/Keywords.php:43
      • 14. app/Http/Controllers/ArticleController.php:2519
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select * from `article_citation` where `article_id` = '133248'
      5.19msalphaeurekaselec_live_10_06_2022Article.php#1570
      Bindings
      • 0: 133248
      Backtrace
      • 13. app/Models/Article.php:1570
      • 14. app/Http/Controllers/ArticleController.php:2520
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select CONCAT_WS(' ',au.first_name, ' ', ifnull(au.initials,''), ' ', au.last_name) as authors, CONCAT(au.last_name, IFNULL(CONCAT(' ', au.initials), ''), ' ', au.first_name) AS authorsRIS, CONCAT_WS(' ',au.last_name, ' ', ifnull(au.initials,''), ' ', au.first_name) as authorsCiteAs, CONCAT_WS(' ',au.first_name, IFNULL(CONCAT(' ', au.initials), ''), IFNULL(CONCAT(' ', au.last_name), '')) as authorsmodal , `au`.*, `af`.`ror_id`, `af`.`institution`, `af`.`department`, `af`.`country`, `af`.`city`, `af`.`address`, (GROUP_CONCAT(TRIM(BOTH ', ' FROM CONCAT(ifnull(concat(af.institution,','),''), ifnull(concat(af.department,','),''), ifnull(concat(af.address,','),''), ifnull(concat(af.city,','),''), ifnull(concat(af.country,','),''), ifnull(concat(af.postal_code,','),''), ifnull(concat(af.phone,','),''), ifnull(concat(af.fax,','),''))) SEPARATOR '|')) as `author_affiliation`, (GROUP_CONCAT(TRIM(BOTH ', ' FROM CONCAT(ifnull(concat(af.web_view,','),''))) SEPARATOR '|')) as `web_view` from `author` as `au` left join `author_affiliation` as `af` on `au`.`author_id` = `af`.`author_id` where `au`.`article_id` = '133248' group by `au`.`author_id` order by `au`.`article_id` asc, `au`.`sequence` asc
      1.34msalphaeurekaselec_live_10_06_2022Author.php#86
      Bindings
      • 0: 133248
      Backtrace
      • 13. app/Models/Author.php:86
      • 14. app/Http/Controllers/ArticleController.php:2533
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select `bo`.* from `bundle_offer` as `bo` where `bo`.`bundle_status` = 'A' order by `bo`.`bundle_id` desc
      210μsalphaeurekaselec_live_10_06_2022BundleOffer.php#57
      Bindings
      • 0: A
      Backtrace
      • 13. app/Models/BundleOffer.php:57
      • 14. app/Http/Controllers/ArticleController.php:2535
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select `subtitle` from `journal` where `continues_publication_journal` = 1
      470μsalphaeurekaselec_live_10_06_2022Article.php#1960
      Bindings
      • 0: 1
      Backtrace
      • 13. app/Models/Article.php:1960
      • 14. app/Http/Controllers/ArticleController.php:2062
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • Select j.subtitle, v.volume_id as volume_id,v.year_id,y.year as year,v.volume_name, v.total_no_of_issues, i.issue_id as issue_id,i.title as issue, i.publication_date as issue_pub_date from journal j join volume v on j.journal_id = v.journal_id join issue i on v.volume_id = i.volume_id join article a on a.issue_id = i.issue_id join year y on v.year_id = y.id where j.journal_id = 18 and i.is_uploaded = 1 order by v.volume_name+0 desc, i.title+0 desc limit 1
      25.05msalphaeurekaselec_live_10_06_2022Issue.php#298
      Backtrace
      • 11. app/Models/Issue.php:298
      • 12. app/Http/Controllers/ArticleController.php:2068
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select a.nid,a.publish_on, a.pmid,a.article_id,a.doi,j.journal_id,j.subtitle,v.volume_name,a.volume_id as volume_id, a.issue_id,a.title,first_page, last_page, page_count,abstract,ifnull(is_abstract,"y"),asec.title as article_section,at.type_name as article_type_name, a.article_id as ArticleID ,is_epub,epub_price,epub_type,a.created, y.year from `article` as `a` left join `article_section` as `asec` on `asec`.`art_sec_id` = `a`.`is_epub` left join `article_type` as `at` on `at`.`art_type_id` = `a`.`art_type` left join `journal` as `j` on `j`.`journal_id` = `a`.`journal_id` inner join `volume` as `v` on `a`.`volume_id` = `v`.`volume_id` inner join `year` as `y` on `v`.`year_id` = `y`.`id` where a.article_status != "W" and a.is_epub = 1 and a.journal_id = 18 and a.is_uploaded = 1 group by `a`.`article_id` order by `a`.`publish_on` desc
      7.99msalphaeurekaselec_live_10_06_2022Article.php#528
      Backtrace
      • 13. app/Models/Article.php:528
      • 14. app/Http/Controllers/ArticleController.php:2070
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select a.nid,a.publish_on, a.pmid,a.article_id,a.doi,j.journal_id,j.subtitle,v.volume_name,a.volume_id as volume_id, a.issue_id,a.title,first_page, last_page, page_count,abstract,ifnull(is_abstract,"y"),asec.title as article_section,at.type_name as article_type_name, a.article_id as ArticleID ,is_epub,epub_price,epub_type,a.created, y.year from `article` as `a` left join `article_section` as `asec` on `asec`.`art_sec_id` = `a`.`is_epub` left join `article_type` as `at` on `at`.`art_type_id` = `a`.`art_type` left join `journal` as `j` on `j`.`journal_id` = `a`.`journal_id` inner join `volume` as `v` on `a`.`volume_id` = `v`.`volume_id` inner join `year` as `y` on `v`.`year_id` = `y`.`id` where a.article_status != "W" and a.is_epub = 4 and a.journal_id = 18 and a.is_uploaded = 1 group by `a`.`article_id` order by `a`.`publish_on` desc
      7.05msalphaeurekaselec_live_10_06_2022Article.php#528
      Backtrace
      • 13. app/Models/Article.php:528
      • 14. app/Http/Controllers/ArticleController.php:2071
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select pdf, html, epub, prc from `article_metrics` where `article_id` = 133248 limit 1
      200μsalphaeurekaselec_live_10_06_2022Article.php#744
      Bindings
      • 0: 133248
      Backtrace
      • 14. app/Models/Article.php:744
      • 15. app/Http/Controllers/ArticleController.php:2091
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from content_by_diseases where content_id = 133248 and content_type = 'article' order by status desc limit 1
      320μsalphaeurekaselec_live_10_06_2022Article.php#751
      Backtrace
      • 11. app/Models/Article.php:751
      • 12. app/Http/Controllers/ArticleController.php:2094
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `node_meta` where `nid` = 219249 limit 1
      180μsalphaeurekaselec_live_10_06_2022Meta.php#30
      Bindings
      • 0: 219249
      Backtrace
      • 14. app/Models/Meta.php:30
      • 15. app/Http/Controllers/ArticleController.php:2101
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select `bo`.* from `bundle_offer` as `bo` where `bo`.`bundle_status` = 'A' order by `bo`.`bundle_id` desc
      220μsalphaeurekaselec_live_10_06_2022BundleOffer.php#57
      Bindings
      • 0: A
      Backtrace
      • 13. app/Models/BundleOffer.php:57
      • 14. app/Http/Controllers/ArticleController.php:2108
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `tbl_ht_submission` as `h` where `h`.`subtitle` = 'CDD' and (h.proposal_closing_date = 0 OR TO_DAYS(FROM_UNIXTIME(h.proposal_closing_date)) >= TO_DAYS(NOW())) order by `h`.`manuscript` asc
      270μsalphaeurekaselec_live_10_06_2022Article.php#2025
      Bindings
      • 0: CDD
      Backtrace
      • 13. app/Models/Article.php:2025
      • 14. app/Http/Controllers/ArticleController.php:2112
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select count(*) as total_count, content_type_access_id as access_type from journal_access where content_type_id = '133248' and content_type = 'a' and ( (from_date <= CURDATE() and to_date >= CURDATE() and perpetual= 0) or (from_date is null and to_date is null and perpetual= 1) )
      350μsalphaeurekaselec_live_10_06_2022ContentAccess.php#647
      Backtrace
      • 11. app/Models/ContentAccess.php:647
      • 12. app/Http/Controllers/ArticleController.php:2186
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select count(*) as total_count, content_type_access_id as access_type from journal_access where content_type_id = '13095' and content_type = 'i' and ( (from_date <= CURDATE() and to_date >= CURDATE() and perpetual= 0) or (from_date is null and to_date is null and perpetual= 1) )
      280μsalphaeurekaselec_live_10_06_2022ContentAccess.php#647
      Backtrace
      • 11. app/Models/ContentAccess.php:647
      • 12. app/Http/Controllers/ArticleController.php:2207
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select count(*) as total_count, content_type_access_id as access_type from journal_access where content_type_id = '3438' and content_type = 'v' and ( (from_date <= CURDATE() and to_date >= CURDATE() and perpetual= 0) or (from_date is null and to_date is null and perpetual= 1) )
      260μsalphaeurekaselec_live_10_06_2022ContentAccess.php#647
      Backtrace
      • 11. app/Models/ContentAccess.php:647
      • 12. app/Http/Controllers/ArticleController.php:2231
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Trial Access" as access_base_text, CASE j.type WHEN 111 THEN true ELSE false END as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"volume" as access_level,"" as issue_id,"" as article_id from `user_access_journal_volume_trail` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51271243 and j.to_ip >=51271243 )) and ((j.from_date <= 1740514295 and j.to_date >= 1740514295 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.volume_id = 3438) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Subscribed" as access_base_text, false as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"volume" as access_level,"" as issue_id,"" as article_id from `user_access_journal_volume_corporate` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51271243 and j.to_ip >=51271243 )) and ((j.from_date <= 1740514295 and j.to_date >= 1740514295 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.volume_id = 3438) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Token Based Access" as access_base_text, false as terms_popup, "R" as content_download_type, j.uc_id as restricted_user_access_key, "v" as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"volume" as access_level,"" as issue_id,"" as article_id from `user_access_journal_volume_token` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51271243 and j.to_ip >=51271243 )) and ((j.from_date <= 1740514295 and j.to_date >= 1740514295 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.volume_id = 3438)
      7.15msalphaeurekaselec_live_10_06_2022UserAccess.php#1266
      Backtrace
      • 13. app/Models/UserAccess/UserAccess.php:1266
      • 14. app/Http/Controllers/ArticleController.php:2272
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Trial Access" as access_base_text, CASE j.type WHEN 111 THEN true ELSE false END as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"issue" as access_level,j.issue_id,"" as article_id from `user_access_issue_trail` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51271243 and j.to_ip >=51271243 )) and ((j.from_date <= 1740514295 and j.to_date >= 1740514295 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.issue_id = 13095) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Subscribed" as access_base_text, false as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"issue" as access_level,j.issue_id,"" as article_id from `user_access_issue_corporate` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51271243 and j.to_ip >=51271243 )) and ((j.from_date <= 1740514295 and j.to_date >= 1740514295 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.issue_id = 13095) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Token Based Access" as access_base_text, false as terms_popup, "R" as content_download_type, j.uc_id as restricted_user_access_key, "v" as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"issue" as access_level,j.issue_id,"" as article_id from `user_access_issue_token` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51271243 and j.to_ip >=51271243 )) and ((j.from_date <= 1740514295 and j.to_date >= 1740514295 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.issue_id = 13095)
      810μsalphaeurekaselec_live_10_06_2022UserAccess.php#1266
      Backtrace
      • 13. app/Models/UserAccess/UserAccess.php:1266
      • 14. app/Http/Controllers/ArticleController.php:2297
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Trial Access" as access_base_text, CASE j.type WHEN 111 THEN true ELSE false END as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"article" as access_level, j.issue_id, j.article_id from `user_access_article_trail` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51271243 and j.to_ip >=51271243 )) and ((j.from_date <= 1740514295 and j.to_date >= 1740514295 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.article_id = 133248) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Subscribed" as access_base_text, false as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"article" as access_level, j.issue_id, j.article_id from `user_access_article_corporate` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51271243 and j.to_ip >=51271243 )) and ((j.from_date <= 1740514295 and j.to_date >= 1740514295 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.article_id = 133248) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Token Based Access" as access_base_text, false as terms_popup, "R" as content_download_type, j.uc_id as restricted_user_access_key, "v" as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"article" as access_level, j.issue_id, j.article_id from `user_access_article_token` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 51271243 and j.to_ip >=51271243 )) and ((j.from_date <= 1740514295 and j.to_date >= 1740514295 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.article_id = 133248)
      810μsalphaeurekaselec_live_10_06_2022UserAccess.php#1266
      Backtrace
      • 13. app/Models/UserAccess/UserAccess.php:1266
      • 14. app/Http/Controllers/ArticleController.php:2329
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `article` where `first_page` < '993' and is_uploaded = 1 and issue_id = 13095 order by cast(first_page as SIGNED) desc limit 1
      600μsalphaeurekaselec_live_10_06_2022Article.php#1819
      Bindings
      • 0: 993
      Backtrace
      • 14. app/Models/Article.php:1819
      • 15. app/Http/Controllers/ArticleController.php:2470
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `article` where `last_page` > '1009' and is_uploaded = 1 and issue_id = 13095 order by cast(first_page as SIGNED) asc limit 1
      560μsalphaeurekaselec_live_10_06_2022Article.php#1831
      Bindings
      • 0: 1009
      Backtrace
      • 14. app/Models/Article.php:1831
      • 15. app/Http/Controllers/ArticleController.php:2472
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select `language_id` from `multilanguage` where `short_code` = 'en'
      210μsalphaeurekaselec_live_10_06_2022ArticleController.php#2497
      Bindings
      • 0: en
      Backtrace
      • 14. app/Http/Controllers/ArticleController.php:2497
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:206
    • select `source_lang_label`, `target_lang_label` from `multilanguage_labels` where `target_lang_id` = 1
      250μsalphaeurekaselec_live_10_06_2022MultiLanguage.php#23
      Bindings
      • 0: 1
      Backtrace
      • 13. app/Models/MultiLanguage.php:23
      • 14. app/Http/Controllers/ArticleController.php:2498
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select `id` from `multilanguage_article` where `article_id` = 133248 limit 1
      3.82msalphaeurekaselec_live_10_06_2022ArticleController.php#2506
      Bindings
      • 0: 133248
      Backtrace
      • 16. app/Http/Controllers/ArticleController.php:2506
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
      • 20. vendor/laravel/framework/src/Illuminate/Routing/Route.php:206
    • select b.banner_link, b.banner_name, b.banner_script, b.banner_remarks, b.banner_file_name, b.banner_placement, bd.content_type, bd.content_id from `tbl_banner` as `b` inner join `tbl_banner_detail` as `bd` on `bd`.`banner_id` = `b`.`banner_id` inner join `users` as `u` on `u`.`id` = `b`.`updated_by` inner join `journal` as `j` on `j`.`journal_id` = `bd`.`content_id` where `b`.`banner_journal` = 1 and `bd`.`content_type` = 'J' and `bd`.`content_id` = 18 and `b`.`banner_from_date` <= 1740514295 and `b`.`banner_to_date` >= 1740514295 and `b`.`banner_status` = 'A' order by `b`.`banner_id` desc
      1.65msalphaeurekaselec_live_10_06_2022Banner.php#95
      Bindings
      • 0: 1
      • 1: J
      • 2: 18
      • 3: 1740514295
      • 4: 1740514295
      • 5: A
      Backtrace
      • 13. app/Models/Banner.php:95
      • 14. app/Http/helpers.php:404
      • 17. vendor/laravel/framework/src/Illuminate/Filesystem/Filesystem.php:124
      • 18. vendor/laravel/framework/src/Illuminate/View/Engines/PhpEngine.php:58
      • 19. vendor/laravel/framework/src/Illuminate/View/Engines/CompilerEngine.php:73
    • select b.banner_link, b.banner_name, b.banner_script, b.banner_remarks, b.banner_file_name, b.banner_placement, bd.content_type, bd.content_id from `tbl_banner` as `b` inner join `tbl_banner_detail` as `bd` on `bd`.`banner_id` = `b`.`banner_id` inner join `users` as `u` on `u`.`id` = `b`.`updated_by` inner join `journal` as `j` on `j`.`journal_id` = `bd`.`content_id` where `b`.`banner_journal` = 1 and `bd`.`content_type` = 'J' and `bd`.`content_id` = 18 and `b`.`banner_from_date` <= 1740514295 and `b`.`banner_to_date` >= 1740514295 and `b`.`banner_status` = 'A' order by `b`.`banner_id` desc
      1.64msalphaeurekaselec_live_10_06_2022Banner.php#95
      Bindings
      • 0: 1
      • 1: J
      • 2: 18
      • 3: 1740514295
      • 4: 1740514295
      • 5: A
      Backtrace
      • 13. app/Models/Banner.php:95
      • 14. app/Http/helpers.php:404
      • 17. vendor/laravel/framework/src/Illuminate/Filesystem/Filesystem.php:124
      • 18. vendor/laravel/framework/src/Illuminate/View/Engines/PhpEngine.php:58
      • 19. vendor/laravel/framework/src/Illuminate/View/Engines/CompilerEngine.php:73
    • select count(*) as aggregate from `uc_cart_products` where cart_id='67d5115805bfeca63162a36ce85347b9'
      350μsalphaeurekaselec_live_10_06_2022Cart.php#271
      Backtrace
      • 15. app/Models/Cart.php:271
      • 16. view::layouts._header:260
      • 18. vendor/laravel/framework/src/Illuminate/Filesystem/Filesystem.php:124
      • 19. vendor/laravel/framework/src/Illuminate/View/Engines/PhpEngine.php:58
      • 20. vendor/laravel/framework/src/Illuminate/View/Engines/CompilerEngine.php:73
    App\Models\MultiLanguage
    1MultiLanguage.php#?
        _token
        6GNVbgTD2Yfj2a8SQz2EbwWsFp2a40UrDBuhDoGu
        uc_cart_id
        67d5115805bfeca63162a36ce85347b9
        _previous
        array:1 [ "url" => "http://alpha.eurekaselect.com/article/133248" ]
        _flash
        array:2 [ "old" => [] "new" => [] ]
        PHPDEBUGBAR_STACK_DATA
        []
        path_info
        /article/133248
        status_code
        200
        
        status_text
        OK
        format
        html
        content_type
        text/html; charset=UTF-8
        request_query
        []
        
        request_request
        []
        
        request_headers
        0 of 0
        array:9 [ "cookie" => array:1 [ 0 => "wayfindertarget=eyJpdiI6Ii9RbmdIR1U2WTN4R285NlV5ZTJnVmc9PSIsInZhbHVlIjoiNjFwV2VBRHhEZHBDVzB5SEZtNEpKN3BMd0NDNytneFJJdWVzTExiRHZIND0iLCJtYWMiOiJiYmExZGZhNDEzOTQ1MTVhM2UxZjc1ODUxYTMyMmMxY2JhYTQwNDNiZDAwNzAyZWQ4ZTk3OWNmZDYxMDc0YTFjIiwidGFnIjoiIn0%3Dwayfindertarget=eyJpdiI6Ii9RbmdIR1U2WTN4R285NlV5ZTJnVmc9PSIsInZhbHVlIjoiNjFwV2VBRHhEZHBDVzB5SEZtNEpKN3BMd0NDNytneFJJdWVzTExiRHZIND0iLCJtYWMiOiJiYmExZGZhNDEzOTQ1" ] "accept-encoding" => array:1 [ 0 => "gzip, deflate" ] "accept" => array:1 [ 0 => "text/html,application/xhtml+xml,application/xml;q=0.9,image/avif,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3;q=0.7" ] "user-agent" => array:1 [ 0 => "Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)" ] "upgrade-insecure-requests" => array:1 [ 0 => "1" ] "cache-control" => array:1 [ 0 => "no-cache" ] "pragma" => array:1 [ 0 => "no-cache" ] "connection" => array:1 [ 0 => "keep-alive" ] "host" => array:1 [ 0 => "alpha.eurekaselect.com" ] ]
        request_cookies
        0 of 0
        array:1 [ "wayfindertarget" => null ]
        response_headers
        0 of 0
        array:5 [ "content-type" => array:1 [ 0 => "text/html; charset=UTF-8" ] "cache-control" => array:1 [ 0 => "no-cache, private" ] "date" => array:1 [ 0 => "Tue, 25 Feb 2025 20:11:35 GMT" ] "set-cookie" => array:2 [ 0 => "XSRF-TOKEN=eyJpdiI6IkRFQU5JOHFOTGJvRDN6bCtlbGlOL0E9PSIsInZhbHVlIjoiNkhlWmlxZFpCSklQVitIVG9IWXNnM2FOTVVvVlBpMVprY0hVYUNrTXFwU1M5c1dkMXIvNTN2dzFYNDhNOFEyUlJTSlVMa2pHZ0NRek13NVR0dlVpdHFYUEYvdU9TV1FSaSsxUjhrTEx6Yjc2M2o3OUgrZkFXNFZwUTZsYWhaa3AiLCJtYWMiOiJhODRmYWQ1ZWM1YTZiNzQxYzVhZTgwMTFhM2M1YzYyMzQwOWZlZjBmNjFmZDY3Y2IwMmRhNjk3MTNhNDU3MzFlIiwidGFnIjoiIn0%3D; expires=Fri, 28 Feb 2025 08:11:35 GMT; Max-Age=216000; path=/; secure; samesite=laxXSRF-TOKEN=eyJpdiI6IkRFQU5JOHFOTGJvRDN6bCtlbGlOL0E9PSIsInZhbHVlIjoiNkhlWmlxZFpCSklQVitIVG9IWXNnM2FOTVVvVlBpMVprY0hVYUNrTXFwU1M5c1dkMXIvNTN2dzFYNDhNOFEyUlJTSlVMa" 1 => "alphaeurekaselectnet_session=eyJpdiI6InFYRWNnMitCT2Z2RTg3TkxtcWJzd1E9PSIsInZhbHVlIjoiUW5Xb1B1SE5qMlhLK25GTHdmQkM5eVhsQVlUbktLVDZWdEhpTFpmQ2UvWFJhT3N2R1h0d2Y4VjJNS1FXSm9EVjdSbHNQK0pCdU40ZStKV1VTZzlldlQxRWM4S2ZNSzZ4WHFDRmhWRU4rcE9RbGp2NmdjeFBNdlFMcEFMVDl0bDgiLCJtYWMiOiIxMzNiNGIyYTA5YTc2MjgxZDljYWQ1MGM3MzljNjdhNzBlOWFjOGE0ZmVhNzVjMWY2MDIwNmNhNTRiMDc0MjljIiwidGFnIjoiIn0%3D; path=/; secure; httponly; samesite=laxalphaeurekaselectnet_session=eyJpdiI6InFYRWNnMitCT2Z2RTg3TkxtcWJzd1E9PSIsInZhbHVlIjoiUW5Xb1B1SE5qMlhLK25GTHdmQkM5eVhsQVlUbktLVDZWdEhpTFpmQ2UvWFJhT3N2R1h0d2Y4VjJ" ] "Set-Cookie" => array:2 [ 0 => "XSRF-TOKEN=eyJpdiI6IkRFQU5JOHFOTGJvRDN6bCtlbGlOL0E9PSIsInZhbHVlIjoiNkhlWmlxZFpCSklQVitIVG9IWXNnM2FOTVVvVlBpMVprY0hVYUNrTXFwU1M5c1dkMXIvNTN2dzFYNDhNOFEyUlJTSlVMa2pHZ0NRek13NVR0dlVpdHFYUEYvdU9TV1FSaSsxUjhrTEx6Yjc2M2o3OUgrZkFXNFZwUTZsYWhaa3AiLCJtYWMiOiJhODRmYWQ1ZWM1YTZiNzQxYzVhZTgwMTFhM2M1YzYyMzQwOWZlZjBmNjFmZDY3Y2IwMmRhNjk3MTNhNDU3MzFlIiwidGFnIjoiIn0%3D; expires=Fri, 28-Feb-2025 08:11:35 GMT; path=/; secureXSRF-TOKEN=eyJpdiI6IkRFQU5JOHFOTGJvRDN6bCtlbGlOL0E9PSIsInZhbHVlIjoiNkhlWmlxZFpCSklQVitIVG9IWXNnM2FOTVVvVlBpMVprY0hVYUNrTXFwU1M5c1dkMXIvNTN2dzFYNDhNOFEyUlJTSlVMa" 1 => "alphaeurekaselectnet_session=eyJpdiI6InFYRWNnMitCT2Z2RTg3TkxtcWJzd1E9PSIsInZhbHVlIjoiUW5Xb1B1SE5qMlhLK25GTHdmQkM5eVhsQVlUbktLVDZWdEhpTFpmQ2UvWFJhT3N2R1h0d2Y4VjJNS1FXSm9EVjdSbHNQK0pCdU40ZStKV1VTZzlldlQxRWM4S2ZNSzZ4WHFDRmhWRU4rcE9RbGp2NmdjeFBNdlFMcEFMVDl0bDgiLCJtYWMiOiIxMzNiNGIyYTA5YTc2MjgxZDljYWQ1MGM3MzljNjdhNzBlOWFjOGE0ZmVhNzVjMWY2MDIwNmNhNTRiMDc0MjljIiwidGFnIjoiIn0%3D; path=/; secure; httponlyalphaeurekaselectnet_session=eyJpdiI6InFYRWNnMitCT2Z2RTg3TkxtcWJzd1E9PSIsInZhbHVlIjoiUW5Xb1B1SE5qMlhLK25GTHdmQkM5eVhsQVlUbktLVDZWdEhpTFpmQ2UvWFJhT3N2R1h0d2Y4VjJ" ] ]
        session_attributes
        0 of 0
        array:5 [ "_token" => "6GNVbgTD2Yfj2a8SQz2EbwWsFp2a40UrDBuhDoGu" "uc_cart_id" => "67d5115805bfeca63162a36ce85347b9" "_previous" => array:1 [ "url" => "http://alpha.eurekaselect.com/article/133248" ] "_flash" => array:2 [ "old" => [] "new" => [] ] "PHPDEBUGBAR_STACK_DATA" => [] ]
        ClearShow all
        Date ↕MethodURLData
        #12025-02-25 20:11:35GET/article/133248414361